Recombinant Human Cbl-B Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Cbl-B Protein, CF Summary

• Additional Information: Will be discontinued when existing inventory is gone.
• Details of Functionality: Typical concentration to support in vitro applications will depend on experimental design.
• Source: Spodoptera frugiperda, Sf 21 (baculovirus)-derived human Cbl-B protein
  Met1 - Leu982
• Accession #: Q13191.2
• Protein/Peptide Type: Recombinant Enzymes
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 110 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.
• Buffer: Supplied as a solution in HEPES, NaCl, Glycerol and DTT.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Cbl-B Protein, CF

• Cas-Br-M (murine) ecotropic retroviral transforming sequence b
• Cas-Br-M (murine) ectropic retroviral transforming sequence b
• Casitas B-lineage lymphoma proto-oncogene b
• CBLB
• Cbl-B
• DKFZp686J10223
• DKFZp779A0729
• DKFZp779F1443
• E3 ubiquitin-protein ligase CBL-B
• EC 6.3.2
• EC 6.3.2.-
• FLJ41152
• Nbla00127
• RING finger protein 56
• RNF56
• RNF56FLJ36865
• SH3-binding protein CBL-B
• Signal transduction protein CBL-B

Background

Cbl-B (Casitas B-lineage lymphoma protooncogene b, aka RNF56) is a member of the Cbl family of RING-type E3 Ubiquitin ligases, and has been implicated in the regulation of pathways associated with cell differentiation, tissue development, skeletal muscle atrophy and adaptive immunity.  Along with its RING-type zinc finger domain, Cbl-B contains an N-terminal tyrosine kinase binding (TKB) domain and a C-terminal UBA (Ubiquitin Associated) domain.  This E3 ligase preferentially interacts with phosphotyrosine-modifed intracellular signaling molecules, targeting them for ubiquitination.  Reported substrates for Cbl-B include VAV1, PIKR1, SYK, SRC, EGFR, AXL and others.  Downregulation of Cbl-B has been shown to remove the requirement for CD28 co-stimulation during T-cell activation, suggesting Cbl-B inhibitors may be useful in various cancer immunotherapies.

1. Kobashigawa, Y. et al. (2011) Proc. Nat. Acad. Sci. 108: 20579.
2. Rorsman, C. et al. (2016) J. Biol. Chem. 291: 11608.
3. Sitaram, P. et al. (2019) Int. J. Mol. Sci. 20: 5821.

Bioinformatics

• Uniprot:
  • Q13191.2()